| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 100.892 | 91.377 | 84.564 | 99.271 | 108.245 | 144.912 | 157.496 | 145.156 | 146.675 | 147.173 |
| Total Income - EUR | 100.931 | 91.728 | 84.569 | 99.276 | 108.252 | 144.946 | 157.514 | 145.201 | 146.845 | 147.228 |
| Total Expenses - EUR | 92.735 | 85.092 | 80.291 | 94.109 | 104.445 | 126.653 | 141.637 | 133.564 | 137.003 | 138.857 |
| Gross Profit/Loss - EUR | 8.196 | 6.636 | 4.279 | 5.167 | 3.807 | 18.293 | 15.877 | 11.637 | 9.843 | 8.370 |
| Net Profit/Loss - EUR | 6.719 | 5.518 | 3.423 | 4.169 | 2.725 | 17.280 | 14.488 | 10.202 | 8.578 | 7.142 |
| Employees | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Pharmacon Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 1.652 | 1.402 | 1.163 | 932 | 1.269 | 920 | 568 |
| Current Assets | 37.672 | 27.634 | 27.404 | 32.587 | 35.011 | 60.857 | 62.576 | 71.640 | 48.317 | 52.508 |
| Inventories | 9.435 | 15.081 | 15.914 | 12.678 | 12.341 | 17.354 | 15.209 | 14.642 | 18.840 | 21.245 |
| Receivables | 9.639 | 2.818 | 8.772 | 13.683 | 8.951 | 11.177 | 8.930 | 5.054 | 4.114 | 3.821 |
| Cash | 18.599 | 9.735 | 2.718 | 6.225 | 13.719 | 32.326 | 38.437 | 51.943 | 25.363 | 27.443 |
| Shareholders Funds | 18.102 | 9.416 | 6.769 | 5.012 | 4.122 | 17.934 | 29.598 | 10.655 | 19.201 | 22.214 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 19.570 | 18.269 | 20.657 | 29.258 | 32.342 | 44.241 | 34.105 | 62.480 | 30.346 | 31.169 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5231 - 5231" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pharmacon Srl